eplerenone应怎么购买？

Launched in the United States in 2002, eplerenone is used for the treatment of hypertension, heart failure and myocardial infarction. It has definite efficacy in treating hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Its outstanding advantage is that for severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. For patients with severe heart failure and myocardial infarction, eplerenone combined with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve quality of life and reduce mortality. 

Eplerenone is a selective aldosterone receptor antagonist that only acts on mineralocorticoid receptors but not on androgen and progesterone receptors. Eplerenone treats patients with stage 1 and stage 2 hypertension with similar efficacy and reduction in systolic and diastolic blood pressure as enalapril. Eplerenone also has a good antihypertensive effect in patients with essential hypertension with low renin levels for whom angiotensin-converting enzyme inhibitors and angiotensin II receptor inhibitors are ineffective. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for patients with hypertension combined with diabetes.

The side effects of eplerenone that have >10% are, endocrine and metabolic: hyperkalemia ([heart failure, post-myocardial infarction: >5.5 meq/L: 16%; ≥6 meq/L: 6%, [hypertension, >5.5 meq/L: 400 mg: 9%; dose ≤200 mg: ≤1%]), hypertriglyceridemia (1%-15%; dose related); 1%-10% Side effects: central nervous system: dizziness (3%), fatigue (2%); endocrinology and metabolism: hyponatremia (2%; dose-related), proteinuria (1%), gynecomastia (≤1%), hypercholesterolemia (≤1%); gastrointestinal tract: diarrhea (2%), abdominal pain (1%); urogenital system: abnormal vaginal bleeding (≤2%), breast pain (men: ≤1%); kidney: increased serum creatinine (heart failure, post-myocardial infarction: 6%); respiratory system: cough (2%), flu-like symptoms (2%).

The therapeutic effect of eplerenone is so effective that patients who need to purchase it can find medical companions from overseas medical institutions in China for consultation.